Clinical Trials Logo

Stargardt Macular Degeneration clinical trials

View clinical trials related to Stargardt Macular Degeneration.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT04239625 Enrolling by invitation - Stargardt Disease Clinical Trials

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

Start date: December 20, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this open-label, multicenter study is to determine the long-term safety, pharmacokinetics and effects of ALK-001 (C20-D3-retinyl acetate) on the progression of Stargardt disease. This study is an extension of NCT02402660 and enrolls participants who are at least 8 years old. Enrollment is by invitation only. Funding Source - FDA OOPD